Related Experiment Video
Updated: Jun 26, 2026
04:44
Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
Are statins useful for treating vascular involvement in systemic sclerosis?
Jelena Blagojevic1, Marco Matucci-Cerinic
1Department of Biomedicine, Reference Center for Systemic Sclerosis, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
Nature Clinical Practice. Rheumatology
|February 3, 2009
Summary
Statins significantly reduced digital ulcers and improved function in systemic sclerosis patients. This study provides evidence for statins in managing vascular complications of this condition.
Area of Science:
- Rheumatology
- Cardiovascular Medicine
Background:
- Systemic sclerosis (SSc) is associated with significant vascular complications, including digital ulcers and Raynaud's phenomenon.
- Previous research indicated statins may improve endothelial function and Raynaud's severity by increasing endothelial precursor cells.
Discussion:
- This study presents the first randomized, double-blind, placebo-controlled trial evaluating statins for vascular manifestations in SSc.
- Findings suggest statins may improve endothelial function, leading to clinical and functional recovery in SSc patients.
Key Insights:
- Statins significantly reduced the overall number and incidence of new digital ulcers in SSc patients.
- Statin therapy led to notable improvements in patient disability scores and overall functional status.
- The results support the potential of statins in managing vascular complications of systemic sclerosis.
Outlook:
- Further large-scale studies are warranted to confirm these findings and establish statins as a standard treatment for vascular complications in SSc.
- This research opens new avenues for therapeutic interventions targeting endothelial dysfunction in systemic sclerosis.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Atherosclerosis IV: Nursing Management
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
01:21Rheumatic Heart Disease III: Medical Management
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...